Published in Liver Transpl on October 01, 2004
Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg (2007) 2.12
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol (2008) 1.37
S6K1 deficiency protects against apoptosis in hepatocytes. Hepatology (2009) 1.11
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Overview of immunosuppression in liver transplantation. World J Gastroenterol (2009) 0.96
Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol (2008) 0.95
Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol (2005) 0.95
Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol (2014) 0.94
Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg (2007) 0.94
New advances in hepatocellular carcinoma. World J Hepatol (2016) 0.91
Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol (2014) 0.90
Impact of rapamycin on liver regeneration. Virchows Arch (2008) 0.87
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant (2014) 0.86
Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World J Gastroenterol (2006) 0.86
Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol (2015) 0.85
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol (2011) 0.84
Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol (2013) 0.83
The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol (2011) 0.82
Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol (2015) 0.81
Historical perspective of living donor liver transplantation. World J Gastroenterol (2008) 0.79
Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence. World J Gastroenterol (2011) 0.79
Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease. Dig Dis Sci (2007) 0.78
Current Treatment Approaches to HCC with a Special Consideration to Transplantation. J Transplant (2016) 0.78
Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma. HPB (Oxford) (2014) 0.78
Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. World J Gastroenterol (2013) 0.78
Hepatocellular cancer, transplantation, and sirolimus. Liver Transpl (2004) 0.75
Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome. ISRN Hepatol (2014) 0.75
Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol (2006) 0.75
Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria. World J Hepatol (2016) 0.75
Contemporary strategies in the management of hepatocellular carcinoma. HPB Surg (2012) 0.75
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75
Five-year follow-up after clinical islet transplantation. Diabetes (2005) 7.86
Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest (2002) 5.52
Gastric adenocarcinoma: review and considerations for future directions. Ann Surg (2005) 3.83
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med (2009) 3.70
Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 3.64
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology (2010) 3.54
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes (2003) 2.62
Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology (2009) 2.51
Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes (2002) 2.36
Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes (2009) 2.31
Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl (2012) 2.26
Retracted Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes (2007) 2.25
Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes (2004) 2.22
Cell encapsulation: promise and progress. Nat Med (2003) 2.18
Thoracoscopic Nuss procedure for young adults with pectus excavatum: excellent midterm results and patient satisfaction. Ann Thorac Surg (2013) 2.18
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Islet graft assessment in the Edmonton Protocol: implications for predicting long-term clinical outcome. Diabetes (2004) 1.98
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant (2007) 1.78
Adult liver transplant survey: policies towards eligibility criteria in Canada and the United States 2007. Liver Int (2008) 1.77
Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines. PLoS One (2012) 1.76
FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. Proc Natl Acad Sci U S A (2002) 1.72
Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet (2010) 1.62
Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes (2002) 1.61
Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transpl Int (2009) 1.58
Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl (2009) 1.55
BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J Leukoc Biol (2009) 1.53
Cardiopulmonary resuscitation with chest compressions during sustained inflations: a new technique of neonatal resuscitation that improves recovery and survival in a neonatal porcine model. Circulation (2013) 1.51
Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology (2002) 1.50
Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol (2008) 1.50
Concern Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes (2006) 1.47
Aging correlates with decreased beta-cell proliferative capacity and enhanced sensitivity to apoptosis: a potential role for Fas and pancreatic duodenal homeobox-1. Diabetes (2006) 1.47
Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes (2004) 1.46
Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. Mol Ther (2002) 1.46
Edmonton's islet success has indeed been replicated elsewhere. Lancet (2003) 1.45
Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a Subcutaneous Cell Pouch Device. Transplantation (2015) 1.44
Hilar early division of the hepatic duct in living donor right hepatectomy: the probe-and-clamp technique. Liver Transpl (2006) 1.44
Staged approach for abdominal wound closure following combined liver and intestinal transplantation from living donors in pediatric patients. Pediatr Transplant (2008) 1.43
Postresuscitation administration of doxycycline preserves cardiac contractile function in hypoxia-reoxygenation injury of newborn piglets*. Crit Care Med (2014) 1.40
Update on islet transplantation. Cold Spring Harb Perspect Med (2012) 1.40
Duplication of MER115 on chromosome 4 in patients with primary biliary cirrhosis. Liver Int (2008) 1.39
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology (2010) 1.38
Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care (2005) 1.35
Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology (2003) 1.34
Strategic opportunities in clinical islet transplantation. Transplantation (2005) 1.34
Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes (2002) 1.32
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet (2012) 1.32
Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int (2004) 1.29
Factors influencing the loss of beta-cell mass in islet transplantation. Cell Transplant (2007) 1.27
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol (2012) 1.27
Current status of clinical islet cell transplantation. Methods Mol Biol (2006) 1.25
The genetics of complex cholestatic disorders. Gastroenterology (2013) 1.24
Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am J Transplant (2005) 1.23
Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes (2006) 1.21
Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health Workshop on Beta Cell Imaging. Transplantation (2004) 1.17
Chemical contamination in southwest Puerto Rico: an assessment of organic contaminants in nearshore sediments. Mar Pollut Bull (2008) 1.14
Enhancing the success of human islet isolation through optimization and characterization of pancreas dissociation enzyme. Am J Transplant (2007) 1.14
Repair of symptomatic giant paraesophageal hernias in elderly (>70 years) patients results in improved quality of life. J Gastrointest Surg (2011) 1.14
Estimation of pancreas weight from donor variables. Cell Transplant (2006) 1.13
Islet isolation and transplantation outcomes of pancreas preserved with University of Wisconsin solution versus two-layer method using preoxygenated perfluorocarbon. Transplantation (2006) 1.12
Histologic graft assessment after clinical islet transplantation. Transplantation (2009) 1.12
XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes (2005) 1.12
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Glucose regulates cyclin D2 expression in quiescent and replicating pancreatic β-cells through glycolysis and calcium channels. Endocrinology (2011) 1.11
Current status of pancreatic islet transplantation. Clin Sci (Lond) (2006) 1.11
Comparison of open and minimally invasive thymectomies at a single institution. Am J Surg (2010) 1.10
Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation (2010) 1.10
Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol (2013) 1.10
Mouse retroviruses and chronic fatigue syndrome: Does X (or P) mark the spot? Proc Natl Acad Sci U S A (2010) 1.09
Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: four cases. Diabetes Care (2011) 1.08
Advances in pancreatic islet transplantation in humans. Diabetes Obes Metab (2006) 1.08
Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther (2006) 1.08
Comparison of human islet isolation outcomes using a new mammalian tissue-free enzyme versus collagenase NB-1. Transplantation (2010) 1.06
Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol (2002) 1.05
Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes (2006) 1.05
Revascularization of transplanted pancreatic islets and role of the transplantation site. Clin Dev Immunol (2013) 1.04
Factors influencing the collagenase digestion phase of human islet isolation. Transplantation (2007) 1.03
Surgical aspects of human islet isolation. Islets (2010) 1.03
Circumportal pancreas and islet isolation. Surgery (2008) 1.03
Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. Hepatology (2013) 1.01
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs (2004) 1.01
Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transpl Int (2008) 1.00
Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant (2004) 1.00
Prediction of cardiac complications after liver transplantation. Transplantation (2009) 1.00
Risks and side effects of islet transplantation. Curr Diab Rep (2004) 1.00